Biohaven Pharmaceuticals Holding Co Ltd (BHVN) Covered Calls

You can sell covered calls on Biohaven Pharmaceuticals Holding Co Ltd to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for BHVN (prices last updated Thu 4:16 PM ET):

Biohaven Pharmaceuticals Holding Co Ltd (BHVN) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
44.74 +0.24 42.89 45.40 398K -6.6 2.3B
Covered Calls For Biohaven Pharmaceuticals Holding Co Ltd (BHVN)
Expiration Strike Call Bid Net Debit Return
If Flat
Return If Flat
Jul 19 45 0.00 45.40 -0.9% -164.2%
Aug 16 45 3.20 42.20 6.6% 80.3%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases. In addition, it develops BHV-3500 for the acute treatment and prevention of migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. The company was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.